Attention-Deficit/Hyperactivity Disorder (ADHD)
Neurodevelopmental Executive Function Disorder
Primary risk age: Preschoolers through Adulthood (Typically diagnosed in school-aged children; more common in boys)
- Urgency
- Moderate
- Typical age
- Preschoolers through Adulthood (Typically diagnosed in school-aged children; more common in boys)
- Body system
- Developmental & Behavioral
Typical course: This is a chronic neurodevelopmental condition; management is ongoing throughout childhood and adolescence.
Reviewed against AAP · CDC · WHO · NHS guidance Last reviewed 2026-06-13
1. Summary & Pathophysiology
Neurodevelopmental Executive Function Disorder
Pathophysiology (Development Path)
Dysregulation of dopamine and norepinephrine pathways in the prefrontal cortex, which governs executive function, impulse control, and working memory. This leads to an inability to regulate attention and behavior.
Primary Causes & Etiology
Strong genetic heritability (up to 75-80%) combined with environmental factors like low birth weight, prenatal tobacco/alcohol exposure, or lead exposure.
2. Symptom Continuum
- Early Onset Signs
Extreme restlessness, difficulty participating in quiet group activities, and high impulsivity in preschool years.
- Progressive Phase
Inattention: difficulty sustaining attention, making careless mistakes, not listening, and losing things. Hyperactivity/Impulsivity: fidgeting, running or climbing inappropriately, interrupting others, and inability to wait their turn.
- Severe Indicators
Severe academic failure, social rejection by peers, dangerous risk-taking behaviors, and high family conflict. Symptoms must be present in multiple settings (home and school) and impair function.
3. Clinical Verification
Clinical evaluation based on DSM-5 criteria, utilizing standardized rating scales (Vanderbilt or Conners) completed by parents and teachers to document symptoms across settings.
4. Care & Elements Plan
Primary Care Treatment Plan
A combination of behavioral therapy (parent training in behavior management) and pharmacotherapy. Stimulant medications are highly effective. Provide classroom accommodations (504 Plan or IEP).
Home Support Elements
Create a highly structured home environment with clear rules and consistent routines. Break homework tasks into small, manageable chunks with frequent breaks. Use positive reinforcement charts.
Generic Active Ingredients (No Brands)
- Methylphenidate hydrochloride or Amphetamine mixed salts (generic central nervous system stimulants used to increase prefrontal dopamine and norepinephrine)
- Atomoxetine (generic non-stimulant active ingredient).
Lists active elements only. Never administer self-designed therapies.
5. Doctor Critical Lines
Critical Thresholds: When to See a Doctor
Consult a pediatrician if your child's inattention, hyperactivity, or impulsivity is causing academic struggle, social difficulties, or behavioral issues in school and at home.
6. Vaccine & Prevention
Routine Prophylaxis (Prevention)
Avoid prenatal exposure to tobacco, alcohol, and lead; ensure adequate nutrition during early development.
Immunization Context
No specific immunizations are associated with this neurodevelopmental condition.
7. Timelines & Outlook
Active Timeline
This is a chronic neurodevelopmental condition; management is ongoing throughout childhood and adolescence.
Expected Prognosis
Good. Many children manage symptoms successfully with therapy and medication. Up to 50-60% of children continue to experience symptoms into adulthood.
Potential Untreated Complications
Academic failure, oppositional defiant disorder, anxiety, depression, low self-esteem, and increased risk of accidents.
More in Neurodevelopmental & Cognitive Spectrum Disorders
Moderate Autism Spectrum Disorder (ASD)
Neurodevelopmental Communication & Behavioral Disorder
Toddlerhood through Adulthood (Signs typically recognizable by 18 to 24 months; more common in boys)
Moderate Pediatric Generalized Anxiety Disorder (GAD)
Chronic Pediatric Neuro-Psychiatric Anxiety Syndrome
School-aged children and adolescents (onset typically after 6 years)
Severe Pediatric Major Depressive Disorder (MDD)
Pediatric Affective Neurotransmitter Deficiency Disorder
Adolescents (peak incidence), though can present in younger school-aged children